Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working Group
制定重新评估流程的考量因素：加拿大癌症药物真实世界价值证据（CanREValue）合作组织重新评估和推广工作组的报告
期刊:Current Oncology
影响因子:3.4
doi:10.3390/curroncol28050354
Dai, Wei Fang; Arciero, Vanessa; Craig, Erica; Fraser, Brent; Arias, Jessica; Boehm, Darryl; Bosnic, Nevzeta; Caetano, Patricia; Chambers, Carole; Jones, Barry; Lungu, Elena; Mitera, Gunita; Potashnik, Tanya; Reiman, Anthony; Ritcher, Trevor; Beca, Jaclyn M; Denburg, Avram; Mercer, Rebecca E; Parmar, Ambica; Tadrous, Mina; Takhar, Pam; Chan, Kelvin K W; On Behalf Of The CanREValue Collaboration Reassessment And Uptake Working Group
